KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Inventory (2017 - 2025)

Ionis Pharmaceuticals has reported Inventory over the past 9 years, most recently at $10.0 million for Q4 2025.

  • Quarterly results put Inventory at $10.0 million for Q4 2025, down 19.69% from a year ago — trailing twelve months through Dec 2025 was $10.0 million (down 19.69% YoY), and the annual figure for FY2025 was $10.0 million, down 19.69%.
  • Inventory for Q4 2025 was $10.0 million at Ionis Pharmaceuticals, down from $10.5 million in the prior quarter.
  • Over the last five years, Inventory for IONS hit a ceiling of $30.3 million in Q1 2024 and a floor of $7.4 million in Q4 2023.
  • Median Inventory over the past 5 years was $22.2 million (2021), compared with a mean of $20.1 million.
  • Biggest five-year swings in Inventory: soared 68.15% in 2024 and later tumbled 70.47% in 2025.
  • Ionis Pharmaceuticals' Inventory stood at $24.8 million in 2021, then dropped by 11.18% to $22.0 million in 2022, then tumbled by 66.23% to $7.4 million in 2023, then soared by 68.15% to $12.5 million in 2024, then fell by 19.69% to $10.0 million in 2025.
  • The last three reported values for Inventory were $10.0 million (Q4 2025), $10.5 million (Q3 2025), and $8.5 million (Q2 2025) per Business Quant data.